2022 Galenica Group sales

Ad hoc announcement pursuant to Art. 53 LR, Thursday, 19 January 2023

Galenica achieves sales of more than CHF 4 billion for the first time thanks to strong growth.

The Galenica Group can once again look back on an exceptionally successful 2022 financial year: consolidated net sales increased by 4.7% to CHF 4,014.3 million. As a result, Galenica slightly exceeded its sales forecast and passed the CHF 4 billion mark for the first time.

Adjusted for additional sales in connection with COVID-19, which were exceptionally high in the prior-year, sales growth was even high at 7.1%. After a normal seasonal flu epidemic and numerous illnesses caused by the coronavirus Omicron variant led to strong growth in the first half of the year 2022, sales for the entire Group were also influenced in the second half of the year by a strong, early-onset flu epidemic. This had a particular impact on the Products & Brands sector, which grew at an above-average rate of 19.8%. In addition, the extremely positive growth momentum of the previous year was continued in the 2022 financial year by the specialty pharmacy Mediservice (+12.9%).

Earnings outlook confirmed

Based on adjusted1 EBIT 2021 – excluding the extraordinary results from the COVID-19 initiatives (estimated at CHF 25 million) and the property sale at its headquarters in Bern (CHF 9.4 million) – an expected EBIT increase of 8% to 12% was communicated with the 2022 half-year results. Thanks to the strong sales growth in the second half of 2022, Galenica expects an EBIT increase at the upper end of this range.

Net sales of the Galenica Group 2022:

 
 

(in Mio. CHF)

2022

2021

Change

Products & Care Segment
- Retail (B2C)
  - Local Pharmacies
  - Pharmacies at Home

2,029.6
1,806.6
1,286.9
519.9

1,908.1
1,720.0
1,261.5
458.8

+6.4%
+5.0%
+2.0
+13.3%

- Professionals (B2B)
  - Products & Brands
  - Services for Professionals


228.8
157.7
71.1

194.0
131.6
62.4

+17.9%
+19.8%
+13.9%

Logistics & IT Segment
- Wholesale
- Logistics & IT Services


2,932.8
2,820.4
130.2

2,831.4
2,728.4
111.9

+3.6%
+3.4%
+16.4%

Corporate and eliminations

-948.1

-904.8


Galenica Group

4,014.3

3,834.7

+4.7%

1 Excluding the effects of IFRS 16 and IAS 19

Additional information on sales figures and further information can be found in our investor presentation.

Other press releases

Contact

Galenica Ltd.

Media
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 17
Mobile +41 79 371 77 24
Fax +41 58 852 85 58

Contact

Galenica Ltd.

Investors
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 29
Fax +41 58 852 85 35